Stoned Stupid

A 2020 study from Society For The Study of Addiction claims that moderate adolescant cannabis use is linked to cognitive impairment that cannot be attributed to familial factors (1).

Why might this be?

Let’s explore this and also how the outcome of cannabis on cognition may depend on mood.

Dynorphin and THC

A lot of research on this blog has focused on a neuropeptide that is under-represented in pop psychology: dynorphin. This neurotransmitter is a kappa opioid receptor agonist, like the hallucinogenic drug Salvia Divinorum (2). This neuropeptide may help in explaining the impairment to cognition observed with moderate cannabis use.

Cannabis (THC) is observed to stimulate dynorphin A release (3, 4). It appears that the ‘dysphoric’ component of THC is mediated by dynorphin as the removal of dynorphin from animals results in a disappearance of the dysphoric effects (3). This makes sense because dynorphin is thought to encode the dysphoric component of stress (5) and pain (6). Dynorphin is also involved in a whole slew of dysphoric mental health issues, such as PTSD (7), depression (8), anxiety (9, 10), and schizophrenia (11, 12, 13).

Dynorphin blocks glutamate NMDA receptors (like ketamine and PCP) (14) which are important for neuroplasticity (15). Dynorphin has been shown to shut down neuroplasticity in the hippocampus (16), a brain region associated to learning and memory. Dynorphin mediates impaired learning and memory that emerges from stress (17), alcohol consumption (18), aging and possibly Alzheimer’s disease (19, 20, 21). Dynorphin is implicated in schizophrenia, a disorder in which patients show impaired cognition and lower IQ (22). Dynorphin has also been found to be increased in individuals with Down syndrome (23).

THC has been found to impair plasticity in the hippocampus even after a single dose (24, 25), but a newer study found enhanced plasticity and neurogenesis and argued that THC cannot be categorized as enhancing or inhibiting plasticity and neurogenesis (26). Chronic use of cannabis is associated to decreased hippocampal volume (27). THC also appears to downregulate NMDA receptors through CB1 receptor activation (28), which suggests that the cognitive impairment is multi-faceted and not entirely dynorphin dependent. Taken together, this research suggests cannabis may impair cognition through increasing dynorphin and CB1 receptor activity to suppress NMDA receptors and thus neuroplasticity.

CBD

CBD is another component of cannabis that is studied often. It seems to have many opposite effects compared with THC (29). It may even prevent the loss of hippocampal grey matter observed with THC use (27).

Something interesting is that CBD has more than one mechanism that may decrease dynorphin activity. One of CBD’s mechanism is serotonin 5HT1a receptor agonism (30), which has been shown to decrease dynorphin activity that normally occurs in response to a dopaminergic (31). Another one of CBD’s mechanisms is agonism of the serotonin 5HT2a receptor (30), a binding target that has been popularly associated to the effects of psilocybin, LSD and other psychedelic drugs. LSD was found to diminish kappa opioid receptor mediated depressant effects (32). 5HT2a receptors have also been shown to enhance acetylcholine release in the hippocampus and prefrontal cortex (33) which is significant because one of acetylcholine’s targets, nAch alpha7, suppresses dynorphin release (34). 5HT2a receptor activity seems to enhance learning and memory (35, 36, 37, 38, 39) (although 38 is dose-dependent with psilocybin), while low density of 5HT2a receptors was linked to cognitive impairment (40). Both 5HT1a and 5HT2a have been linked to suppressing aversion (76, 77, 78, 30), which fits well since dynorphin is implicated in stress and pain aversion and these mechanisms seem to suppress dynorphin.

CBD has also been proposed to treat schizophrenia (41), anxiety (42), and depression(43), and also increase hedonic tone (44) which may work partly by decreasing dynorphin activity. It seems that applying CBD with THC reduces the psychotic effects of THC (29). I’ve proposed that 5HT2a receptor agonists may be able to treat schizophrenia in Dynorphin Theory.

Mood-Dependent Cognitive Ability?

Might the impact of cannabis on cognition be mood dependent? It is possible. There are cannabis users who claim to have increased cognitive ability and creativity under the influence of cannabis. Some research suggests that, contrary to patients with schizophrenia, bipolar individuals may experience enhanced cognitive function from cannabis use (46, 47).

Both schizophrenia and bipolar disorder have overlapping symptoms and connections, often viewed as closely related disorders. Despite this, there are actually lines of evidence suggesting there are opposite trends of associations between schizophrenia and bipolar disorder. For example, while schizophrenia is linked to decreased IQ (22), bipolar disorder has associated to high IQ and intelligence in multiple studies (48, 49, 50, 51, 52, 53), a contrary pattern that even showed up in a genome-wide association study (53). Schizophrenia was associated with decreased creativity (measured as divergent thinking), while bipolar mania and schizotypy were associated to increased creativity (54). A personality trait known as openness to experience was observed to be low in schizophrenia (55) but high in those with bipolar disorder (56). While schizophrenia appears to involve heightened dynorphin, individuals with bipolar disorder had almost 50% lower levels of dynorphin compared to normal (57) and dynorphin mimetic drugs are proposed to treat bipolar mania without their usual psychotic side effects (58). While CBD seems to help with schizophrenia, it does not seem to help with bipolar mania (59) and has even been associated to induction of mania in a case study (60).

If you are following along, you may have noticed that, yes, I am claiming that psychosis is more like salvia, while mania may be closer to psychedelia.

A clear distinction is that schizophrenia is generally associated to negative or neutral affect and reduced sensitivity to reward (even reduced mu opioid receptors), but intact aversion (61, 62, 63), while bipolar is associated to swings to states of very high positive affect, known as manic episodes. Historically, mania has been associated to creativity and genius in the popular culture. Perhaps the differing reaction to cannabis between these two conditions is due to the variable of mood.

Whether cannabis induces increased creativity, enhanced cognition, or the opposite may depend on mood. There is evidence from a meta-analysis that positive mood is linked to enhanced creativity compared to neutral or negative mood (64). On the other hand, aversive states have been linked to decreased cognitive abilities. A 14 IQ drop has been observed in conditions of stress and scarcity (65). PTSD has also associated with low intelligence (66, 67, 68) and traumatic experiences have been observed to suppress IQ performance (69), which makes sense because stress impairs plasticity (70, 71) and involves dynorphin activity.

These patterns in the research suggest that negative affect may reduce cognitive ability and positive affect may increase cognitive ability in some cases. Since THC can produce good or bad trips and influences both the reward opioid system (72) and the dysphoric opioid system (dynorphin), it may be that the outcome of cannabis on cognition is covariant with mood and potentially THC to CBD ratios. We might even discover that the induced or reduced neurogenesis and plasticity by THC is dependent on mood. Something to consider is that repeated use of cannabis is associated to depressive effects (75). Lastly, consider that the U.S. government funds research that shows Cannabis is harmful.

Important Clarification

A clarification is needed for study 57, which notes decreased dynorphin in structures of the amygdalas of both depressed and bipolar suicide victims. Dynorphin is thought to play a role in depression, but those with bipolar disorder, and especially those who are dysphoric-manic episodes commit suicides at higher rates than those with depression (73, 74). So it seems that when one has decreased dynorphin, they may become disinhibited and more willing to take the leap into suicide. Presumably dysphoric mania is a sweet spot of suffering and motivation that allows suicide.

. . .

Special thanks to the six patrons: Melissa Bradley, Morgan Catha, Niklas Kokkola, Abhishaike Mahajan, Riley Fitzpatrick, and Charles Wright! Abhi is also the artist who created the cover image for Most Relevant. Please support him on instagram, he is an amazing artist! I’d also like to thank Annie Vu, Chris Byrd, and Kettner Griswold for your kindness and making these projects and the podcast possible through your donations.

If you’d like to support these projects like this, check out this page.

If you liked this, follow me on

Twitter

You can also follow the discussion for this post on Reddit:

r/DrugNerds

r/Nootropics

r/SlateStarCodex

CITATIONS

1. Ellingson, J. M., Ross, J. M., Winiger, E., Stallings, M. C., Corley, R. P., Friedman, N. P., Hewitt, J. K., Tapert, S. F., Brown, S. A., Wall, T. L., and Hopfer, C. J. (2020) Familial factors may not explain the effect of moderate‐to‐heavy cannabis use on cognitive functioning in adolescents: a sibling‐comparison study. Addiction, https://doi.org/10.1111/add.15207.
2. Maqueda, A. E., Valle, M., Addy, P. H., Antonijoan, R. M., Puntes, M., Coimbra, J., … & Barker, S. (2015). Salvinorin-A induces intense dissociative effects, blocking external sensory perception and modulating interoception and sense of body ownership in humans. International Journal of Neuropsychopharmacology, 18(12), pyv065.
3. Zimmer, A., Valjent, E., König, M., Zimmer, A. M., Robledo, P., Hahn, H., … & Maldonado, R. (2001). Absence of Δ-9-tetrahydrocannabinol dysphoric effects in dynorphin-deficient mice. Journal of Neuroscience, 21(23), 9499-9505.
4. Mason Jr, D. J., Lowe, J., & Welch, S. P. (1999). Cannabinoid modulation of dynorphin A: correlation to cannabinoid-induced antinociception. European journal of pharmacology, 378(3), 237-248.
5. Land, B. B., Bruchas, M. R., Lemos, J. C., Xu, M., Melief, E. J., & Chavkin, C. (2008). The dysphoric component of stress is encoded by activation of the dynorphin κ-opioid system. Journal of Neuroscience, 28(2), 407-414.
6. Massaly, N., Copits, B. A., Wilson-Poe, A. R., Hipólito, L., Markovic, T., Yoon, H. J., … & Klaas, A. (2019). Pain-induced negative affect is mediated via recruitment of the nucleus accumbens kappa opioid system. Neuron, 102(3), 564-573.
7. Bailey, C. R., Cordell, E., Sobin, S. M., & Neumeister, A. (2013). Recent progress in understanding the pathophysiology of post-traumatic stress disorder. CNS drugs, 27(3), 221-232.
8. Tejeda, H. A., & Bonci, A. (2019). Dynorphin/kappa-opioid receptor control of dopamine dynamics: Implications for negative affective states and psychiatric disorders. Brain research, 1713, 91-101.
9. Bruchas, M. R., Land, B. B., Lemos, J. C., & Chavkin, C. (2009). CRF1-R activation of the dynorphin/kappa opioid system in the mouse basolateral amygdala mediates anxiety-like behavior. PloS one, 4(12), e8528.
10. Crowley, N. A., Bloodgood, D. W., Hardaway, J. A., Kendra, A. M., McCall, J. G., Al-Hasani, R., … & Lowell, B. B. (2016). Dynorphin controls the gain of an amygdalar anxiety circuit. Cell reports, 14(12), 2774-2783.
11. Heikkilä, L., Rimón, R., & Ternius, L. (1990). Dynorphin A and substance P in the cerebrospinal fluid of schizophrenic patients. Psychiatry research, 34(3), 229-236.
12. Moustafa, S. R., Al-Rawi, K. F., Stoyanov, D., Al-Dujaili, A. H., Supasitthumrong, T., Al-Hakeim, H. K., & Maes, M. (2020). The Endogenous Opioid System in Schizophrenia and Treatment Resistant Schizophrenia: Increased Plasma Endomorphin 2, and κ and μ Opioid Receptors Are Associated with Interleukin-6. Diagnostics, 10(9), 633.
13. Clark, S. D., & Abi-Dargham, A. (2019). The role of dynorphin and the kappa opioid receptor in the symptomatology of schizophrenia: A review of the evidence. Biological psychiatry, 86(7), 502-511.
14. Chen, L., Gu, Y., & Huang, L. Y. (1995). The mechanism of action for the block of NMDA receptor channels by the opioid peptide dynorphin. Journal of Neuroscience, 15(6), 4602-4611.
15. Lüscher, C., & Malenka, R. C. (2012). NMDA receptor-dependent long-term potentiation and long-term depression (LTP/LTD). Cold Spring Harbor perspectives in biology, 4(6), a005710.
16. Wagner, J. J., Terman, G. W., & Chavkin, C. (1993). Endogenous dynorphins inhibit excitatory neurotransmission and block LTP induction in the hippocampus. Nature, 363(6428), 451-454.
17. Carey, A. N., Lyons, A. M., Shay, C. F., Dunton, O., & McLaughlin, J. P. (2009). Endogenous κ opioid activation mediates stress-induced deficits in learning and memory. Journal of Neuroscience, 29(13), 4293-4300.
18. Kuzmin, A., Chefer, V., Bazov, I., Meis, J., Ögren, S. O., Shippenberg, T., & Bakalkin, G. (2013). Upregulated dynorphin opioid peptides mediate alcohol-induced learning and memory impairment. Translational psychiatry, 3(10), e310-e310.
19. Ménard, C., Tse, Y. C., Cavanagh, C., Chabot, J. G., Herzog, H., Schwarzer, C., … & Quirion, R. (2013). Knockdown of prodynorphin gene prevents cognitive decline, reduces anxiety, and rescues loss of group 1 metabotropic glutamate receptor function in aging. Journal of Neuroscience, 33(31), 12792-12804.
20. Jiang, H. K., Owyang, V. V., Hong, J. S., & Gallagher, M. (1989). Elevated dynorphin in the hippocampal formation of aged rats: relation to cognitive impairment on a spatial learning task. Proceedings of the National Academy of Sciences, 86(8), 2948-2951.
21. Ménard, C., Herzog, H., Schwarzer, C., & Quirion, R. (2014). Possible role of dynorphins in Alzheimer’s disease and age-related cognitive deficits. Neurodegenerative Diseases, 13(2-3), 82-85.
22. David, A. S., Malmberg, A., Brandt, L., Allebeck, P., & Lewis, G. (1997). IQ and risk for schizophrenia: a population-based cohort study. Psychological medicine, 27(6), 1311-1323.
23. Risser, D., You, Z. B., Cairns, N., Herrera-Marschitz, M., Seidl, R., Schneider, C., … & Lubec, G. (1996). Endogenous opioids in frontal cortex of patients with Down syndrome. Neuroscience letters, 203(2), 111-114.
24. Fan, N., Yang, H., Zhang, J., & Chen, C. (2010). Reduced expression of glutamate receptors and phosphorylation of CREB are responsible for in vivoΔ9‐THC exposure‐impaired hippocampal synaptic plasticity. Journal of neurochemistry, 112(3), 691-702.
25. Mato, S., Chevaleyre, V., Robbe, D., Pazos, A., Castillo, P. E., & Manzoni, O. J. (2004). A single in-vivo exposure to Δ9THC blocks endocannabinoid-mediated synaptic plasticity. Nature neuroscience, 7(6), 585-586.
26. Suliman, N. A., Taib, C. N. M., Moklas, M. A. M., & Basir, R. (2018). Delta-9-Tetrahydrocannabinol (∆ 9-THC) induce neurogenesis and improve cognitive performances of male sprague dawley rats. Neurotoxicity research, 33(2), 402-411.
27. Demirakca, T., Sartorius, A., Ende, G., Meyer, N., Welzel, H., Skopp, G., … & Hermann, D. (2011). Diminished gray matter in the hippocampus of cannabis users: possible protective effects of cannabidiol. Drug and alcohol dependence, 114(2-3), 242-245.
28. Sánchez-Blázquez, P., Rodríguez-Muñoz, M., & Garzón, J. (2014). The cannabinoid receptor 1 associates with NMDA receptors to produce glutamatergic hypofunction: implications in psychosis and schizophrenia. Frontiers in pharmacology, 4, 169.
29. Bhattacharyya, S., Morrison, P. D., Fusar-Poli, P., Martin-Santos, R., Borgwardt, S., Winton-Brown, T., … & Mehta, M. A. (2010). Opposite effects of Δ-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology, 35(3), 764-774.
30. de Paula Soares, V., Campos, A. C., de Bortoli, V. C., Zangrossi Jr, H., Guimarães, F. S., & Zuardi, A. W. (2010). Intra-dorsal periaqueductal gray administration of cannabidiol blocks panic-like response by activating 5-HT1A receptors. Behavioural brain research, 213(2), 225-229.
31. Tomiyama, M., Kimura, T., Maeda, T., Kannari, K., Matsunaga, M., & Baba, M. (2005). A serotonin 5-HT1A receptor agonist prevents behavioral sensitization to L-DOPA in a rodent model of Parkinson’s disease. Neuroscience research, 52(2), 185-194.
32. Sakloth, F., Leggett, E., Moerke, M. J., Townsend, E. A., Banks, M. L., & Negus, S. S. (2019). Effects of acute and repeated treatment with serotonin 5-HT2A receptor agonist hallucinogens on intracranial self-stimulation in rats. Experimental and clinical psychopharmacology, 27(3), 215.
33. Nair, S. G., & Gudelsky, G. A. (2004). Activation of 5‐HT2 receptors enhances the release of acetylcholine in the prefrontal cortex and hippocampus of the rat. Synapse, 53(4), 202-207.
34. Ji, L., Chen, Y., Wei, H., Feng, H., Chang, R., Yu, D., … & Zhang, M. (2019). Activation of alpha7 acetylcholine receptors reduces neuropathic pain by decreasing dynorphin A release from microglia. Brain research, 1715, 57-65.
35. Gimpl, M. P., Gormezano, I., & Harvey, J. A. (1979). Effects of LSD on learning as measured by classical conditioning of the rabbit nictitating membrane response. Journal of Pharmacology and Experimental Therapeutics, 208(2), 330-334.
36. Romano, A. G., Quinn, J. L., Li, L., Dave, K. D., Schindler, E. A., Aloyo, V. J., & Harvey, J. A. (2010). Intrahippocampal LSD accelerates learning and desensitizes the 5-HT 2A receptor in the rabbit, Romano et al. Psychopharmacology, 212(3), 441-448.
37. Buchborn, T., Schröder, H., Höllt, V., & Grecksch, G. (2014). Repeated lysergic acid diethylamide in an animal model of depression: normalisation of learning behaviour and hippocampal serotonin 5-HT2 signalling. Journal of Psychopharmacology, 28(6), 545-552.
38. Catlow, B. J., Song, S., Paredes, D. A., Kirstein, C. L., & Sanchez-Ramos, J. (2013). Effects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditioning. Experimental brain research, 228(4), 481-491.
39. Zhang, G., & Stackman Jr, R. W. (2015). The role of serotonin 5-HT2A receptors in memory and cognition. Frontiers in pharmacology, 6, 225.
40. Hasselbalch, S. G., Madsen, K., Svarer, C., Pinborg, L. H., Holm, S., Paulson, O. B., … & Knudsen, G. M. (2008). Reduced 5-HT2A receptor binding in patients with mild cognitive impairment. Neurobiology of aging, 29(12), 1830-1838.
41. McGuire, P., Robson, P., Cubala, W. J., Vasile, D., Morrison, P. D., Barron, R., … & Wright, S. (2018). Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial. American Journal of Psychiatry, 175(3), 225-231.
42. Blessing, E. M., Steenkamp, M. M., Manzanares, J., & Marmar, C. R. (2015). Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics, 12(4), 825-836.
43. Linge, R., Jiménez-Sánchez, L., Campa, L., Pilar-Cuéllar, F., Vidal, R., Pazos, A., … & Díaz, Á. (2016). Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-HT/glutamate neurotransmission: role of 5-HT1A receptors. Neuropharmacology, 103, 16-26.
44. Shoval, G., Shbiro, L., Hershkovitz, L., Hazut, N., Zalsman, G., Mechoulam, R., & Weller, A. (2016). Prohedonic effect of cannabidiol in a rat model of depression. Neuropsychobiology, 73(2), 123-129.
45. Hashimoto, T., Kitamura, N., Kajimoto, Y., Shirai, Y., Shirakawa, O., Mita, T., … & Tanaka, C. (1993). Differential changes in serotonin 5-HT 1A and 5-HT 2 receptor binding in patients with chronic schizophrenia. Psychopharmacology, 112(1), S35-S39.
46. Ringen, P. A., Vaskinn, A., Sundet, K., Engh, J. A., Jonsdottir, H., Simonsen, C., … & Andreassen, O. A. (2010). Opposite relationships between cannabis use and neurocognitive functioning in bipolar disorder and schizophrenia. Psychological Medicine, 40(8), 1337.
47. Braga, R. J., Burdick, K. E., DeRosse, P., & Malhotra, A. K. (2012). Cognitive and clinical outcomes associated with cannabis use in patients with bipolar I disorder. Psychiatry research, 200(2-3), 242-245.
48. Gale, C. R., Batty, G. D., McIntosh, A. M., Porteous, D. J., Deary, I. J., & Rasmussen, F. (2013). Is bipolar disorder more common in highly intelligent people? A cohort study of a million men. Molecular psychiatry, 18(2), 190-194.
49. Smith, D. J., Anderson, J., Zammit, S., Meyer, T. D., Pell, J. P., & Mackay, D. (2015). Childhood IQ and risk of bipolar disorder in adulthood: prospective birth cohort study. BJPsych open, 1(1), 74-80.
50. Tiihonen, J., Haukka, J., Henriksson, M., Cannon, M., Kieseppä, T., Laaksonen, I., … & Lönnqvist, J. (2005). Premorbid intellectual functioning in bipolar disorder and schizophrenia: results from a cohort study of male conscripts. American Journal of Psychiatry, 162(10), 1904-1910.
51. MacCabe, J. H., Lambe, M. P., Cnattingius, S., Sham, P. C., David, A. S., Reichenberg, A., … & Hultman, C. M. (2010). Excellent school performance at age 16 and risk of adult bipolar disorder: national cohort study. The British Journal of Psychiatry, 196(2), 109-115.
52. Shen, S. Q., Kim-Han, J. S., Cheng, L., Xu, D., Gokcumen, O., Hughes, A. E., … & Corbo, J. C. (2019). A candidate causal variant underlying both higher intelligence and increased risk of bipolar disorder. bioRxiv, 580258.
53. Smeland, O. B., Bahrami, S., Frei, O., Shadrin, A., O’Connell, K., Savage, J., … & Ueland, T. (2020). Genome-wide analysis reveals extensive genetic overlap between schizophrenia, bipolar disorder, and intelligence. Molecular psychiatry, 25(4), 844-853.
54. Rodrigue, A. L., & Perkins, D. R. (2012). Divergent thinking abilities across the schizophrenic spectrum and other psychological correlates. Creativity Research Journal, 24(2-3), 163-168.
55. Ohi, K., Shimada, T., Nitta, Y., Kihara, H., Okubo, H., Uehara, T., & Kawasaki, Y. (2016). The Five-Factor Model personality traits in schizophrenia: A meta-analysis. Psychiatry Research, 240, 34-41.
56. Barnett, J. H., Huang, J., Perlis, R. H., Young, M. M., Rosenbaum, J. F., Nierenberg, A. A., … & Smoller, J. W. (2011). Personality and bipolar disorder: dissecting state and trait associations between mood and personality. Psychological medicine, 41(8), 1593.
57. Hurd, Y. L. (2002). Subjects with major depression or bipolar disorder show reduction of prodynorphin mRNA expression in discrete nuclei of the amygdaloid complex. Molecular psychiatry, 7(1), 75-81.
58. Zarate Jr, C. A., & Manji, H. K. (2008). Bipolar disorder: candidate drug targets. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine: A Journal of Translational and Personalized Medicine, 75(3), 226-247.
59. Zuardi, A. W., Crippa, J. A. S., Dursun, S. M., Morais, S. L., Vilela, J. A. A., Sanches, R. F., & Hallak, J. E. C. (2010). Cannabidiol was ineffective for manic episode of bipolar affective disorder. Journal of Psychopharmacology, 24(1), 135-137.
60. Ismail, Z. (2018). Dispensary cannabidiol marijuana and first-episode mania. Journal of Psychiatry & Neuroscience: JPN, 43(3), 215.
61. Strauss, G. P., Wilbur, R. C., Warren, K. R., August, S. M., & Gold, J. M. (2011). Anticipatory vs. consummatory pleasure: what is the nature of hedonic deficits in schizophrenia?. Psychiatry Research, 187(1-2), 36-41.
62. Cheng, G. L., Tang, J. C., Li, F. W., Lau, E. Y., & Lee, T. M. (2012). Schizophrenia and risk-taking: impaired reward but preserved punishment processing. Schizophrenia research, 136(1-3), 122-127.
63. Ashok, A. H., Myers, J., Marques, T. R., Rabiner, E. A., & Howes, O. D. (2019). Reduced mu opioid receptor availability in schizophrenia revealed with [11 C]-carfentanil positron emission tomographic Imaging. Nature communications, 10(1), 1-9.
64. Baas, M., De Dreu, C. K., & Nijstad, B. A. (2008). A meta-analysis of 25 years of mood-creativity research: Hedonic tone, activation, or regulatory focus?. Psychological bulletin, 134(6), 779.
65. Mullainathan, S. (2014). FREEING UP. Scientific American Mind.
66. Kira, I., Lewandowski, L., Somers, C. L., Yoon, J. S., & Chiodo, L. (2012). The effects of trauma types, cumulative trauma, and PTSD on IQ in two highly traumatized adolescent groups. Psychological Trauma: Theory, Research, Practice, and Policy, 4(1), 128.
67. Saltzman, K. M., Weems, C. F., & Carrion, V. G. (2006). IQ and posttraumatic stress symptoms in children exposed to interpersonal violence. Child Psychiatry and Human Development, 36(3), 261-272.
68. Brandes, D., Ben-Schachar, G., Gilboa, A., Bonne, O., Freedman, S., & Shalev, A. Y. (2002). PTSD symptoms and cognitive performance in recent trauma survivors. Psychiatry research, 110(3), 231-238.
69. Koenen, K. C., Moffitt, T. E., Caspi, A., Taylor, A., & Purcell, S. (2003). Domestic violence is associated with environmental suppression of IQ in young children. Development and psychopathology, 15(2), 297-311.
70. Artola, A., Von Frijtag, J. C., Fermont, P. C., Gispen, W. H., Schrama, L. H., Kamal, A., & Spruijt, B. M. (2006). Long‐lasting modulation of the induction of LTD and LTP in rat hippocampal CA1 by behavioural stress and environmental enrichment. European Journal of Neuroscience, 23(1), 261-272.
71. Sapolsky, R. M. (2003). Stress and plasticity in the limbic system. Neurochemical research, 28(11), 1735-1742.
72. Roth-Deri, I., Green-Sadan, T., & Yadid, G. (2008). β-Endorphin and drug-induced reward and reinforcement. Progress in neurobiology, 86(1), 1-21.
73. Rihmer, Z., & Kiss, K. (2002). Bipolar disorders and suicidal behaviour. Bipolar Disorders, 4, 21-25.
74. Goldberg, J. F., Garno, J. L., Portera, L., Leon, A. C., Kocsis, J. H., & Whiteside, J. E. (1999). Correlates of suicidal ideation in dysphoric mania. Journal of Affective disorders, 56(1), 75-81.
75. Lev-Ran, S., Roerecke, M., Le Foll, B., George, T. P., McKenzie, K., & Rehm, J. (2014). The association between cannabis use and depression: a systematic review and meta-analysis of longitudinal studies. Psychological medicine, 44(4), 797.
76. Melo, L. L., & Brandão, M. L. (1995). Role of 5-HT1A and 5-HT2 receptors in the aversion induced by electrical stimulation of inferior colliculus. Pharmacology Biochemistry and Behavior, 51(2-3), 317-321.
77. Nogueira, R. L., & Graeff, F. G. (1995). Role of 5-HT receptor subtypes in the modulation of dorsal periaqueductal gray generated aversion. Pharmacology Biochemistry and Behavior, 52(1), 1-6.
78. Kuypers, K. P., De La Torre, R., Farre, M., Pizarro, N., Xicota, L., & Ramaekers, J. G. (2018). MDMA-induced indifference to negative sounds is mediated by the 5-HT 2A receptor. Psychopharmacology, 235(2), 481-490.